SPDR S&P Biotech ETF Sees Significant Outflows Amid Market Fluctuations
Looking at the latest data from ETF Channel, the SPDR S&P Biotech ETF (Symbol: XBI) has shown a significant decline, with an approximate $76.4 million outflow. This marks a 1.2% decrease in shares outstanding, falling from 66,900,000 to 66,075,000. Today’s trading also reflects mixed results for XBI’s key components: Neurocrine Biosciences, Inc. (Symbol: NBIX) has decreased by about 0.5%, while Alnylam Pharmaceuticals Inc (Symbol: ALNY) and United Therapeutics Corp (Symbol: UTHR) have seen increases of approximately 2.2% and 0.8%, respectively. For a full list of holdings, check the XBI Holdings page »
XBI’s Price Performance Over the Past Year
Examining the chart above reveals that XBI’s 52-week range has seen a low of $81.14 and a high of $105.47, considering the last trading price at $94.47. Comparing this price to the 200-day moving average can provide further technical insights—learn more about the 200-day moving average ».
Free Report: Top 8%+ Dividends (paid monthly)
Exchange traded funds (ETFs) operate similarly to stocks, with investors buying and selling “units” instead of conventional shares. These units can be created or destroyed depending on investor demand. Each week, we monitor changes in shares outstanding to identify ETFs experiencing significant inflows or outflows. Notably, the creation of new units requires purchasing the underlying holdings, while the destruction of units entails selling those holdings. Consequently, large movements can impact the individual securities within the ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
Also see:
- Funds Holding TMFE
- Funds Holding CORI
- HSAQ market cap history
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
